Report of Foreign Issuer (6-k)

---

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549
______________________

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

 

For the month of June 2018

 

Commission File Number: 001-36349

 

  MediWound Ltd.
(Translation of registrant ’ s name into English)

 

42 Hayarkon Street

Yavne, 8122745 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒           Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

 

---

 

EXPLANATORY NOTE

 

On June 11, 2018, MediWound Ltd. (the “Company”) issued a press release entitled "MediWound Completes Enrollment in NexoBrid ^® U.S. Phase 3 DETECT Study”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

 

This Report on Form 6-K incorporated   by reference the information contained in Exhibits 99.1 (but excluding quotes of senior management) into the Company’s Registration Statements on Form S-8 filed with the SEC on April 28, 2014 (Registration No. 333-195517), on Form F-3 filed with the SEC on January 25, 2016 (Registration No. 333-209106) and on Forms S-8 filed with the SEC on March 24, 2016 and March 19, 2018 (Registration No. 333-210375 and 333-223267, respectively).

2

---

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	MEDIWOUND LTD.
Date: June 11, 2018	By:	/s/ Sharon Malka
		Name: Sharon Malka
		Title: Chief Financial and Operations Officer

 

 

3

---

 

EXHIBIT INDEX

 

The following exhibit is filed as part of this Form 6-K:

 

Exhibit	Description
99.1	Press release dated June 11, 2018 titled MediWound Completes Enrollment in NexoBrid ® U.S. Phase 3 DETECT Study ".

 

4

---